Basic Information
Quadramet
Regulatory Information
EMEA/H/C/000150
February 4, 1998
15
June 3, 2015
Company Information
France
Route Nationale 306, Saclay B.P. 32 F-91192 Gif sur Yvette Cedex
CIS BIO INTERNATIONAL
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Quadramet is indicated for the relief of bone pain in patients with multiple painful osteoblastic skeletal metastases which take up technetium \[99mTc\]-labelled biphosphonates on bone scan. The presence of osteoblastic metastases which take up technetium \[99mTc\]-labelled biphosphonates should be confirmed prior to therapy.
Overview Summary
This is a summary of the European public assessment report (EPAR). It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the studies performed, to reach its recommendations on how to use the medicine. If you need more information about your medical condition or your treatment, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. If you want more information on the basis of the CHMP recommendations, read the scientific discussion (also part of the EPAR).